Phasya

Phasya operates at the intersection of eye tracking, automotive safety, medical diagnostics, and research software. Its differentiation is the combination of ocular measurement with inferred physiological and cognitive states, including drowsiness, stress, attention, cognitive load, and mind wandering. The Drowsimeter R100 adds a dedicated hardware reference point for high-speed eye-image capture, while the PCSM software portfolio and driver-occupant monitoring tools extend the proposition into software and validation services. In automotive driver monitoring, Phasya is adjacent to established specialists such as Seeing Machines and Smart Eye, both of which focus heavily on camera-based monitoring of driver attention and fatigue. Tobii is a particularly relevant strategic comparator and parent-company context because its broader eye-tracking capabilities complement Phasya's state-detection expertise. Phasya's disclosed seed-stage funding of $1.1 million is modest relative to scaled automotive platforms, suggesting a specialist technology position rather than a broad commercial platform.

Phasya's trajectory shows a progression from research-oriented eye measurement toward applied monitoring systems. Founded in 2014, the company raised a $1,099,333 seed round on Jan 21, 2019 from four investors, providing capital for development of its eye-imaging hardware, physiological-state algorithms, and commercial applications. Its product scope expanded beyond drowsiness detection to include stress, distraction, cognitive load, attention, and mind wandering, with offerings covering the Drowsimeter R100, PCSM software, driver and occupant monitoring, and test and validation services. The clearest inflection point came on Aug 5, 2021, when Tobii acquired Phasya to enter or strengthen its position in automotive driver monitoring. That event likely changed Phasya's growth model from standalone fundraising and customer development to strategic integration within Tobii. The company is listed with a 1-10 employee range and three highlighted current positions, indicating a compact specialist team. No hiring acceleration, layoffs, later funding rounds, or product-launch milestones are disclosed. Consequently, the available evidence supports a technology-led acquisition trajectory, but does not establish independent post-acquisition revenue growth, headcount expansion, or broader commercialization.